panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00842257
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase II Study of Irinotecan and Panitumumab
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Weijing Sun, MD, FACP
- Target Recruit Count
- 24
- Registration Number
- NCT00836277
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 285
- Registration Number
- NCT00819780
- Locations
- 🇪🇸
Research Site, San Sebastián De Los Reyes, Madrid, Spain
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Robert Ferris
- Target Recruit Count
- 46
- Registration Number
- NCT00798655
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
- Conditions
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00792363
- Locations
- 🇩🇰
Vejle Hospital, Dept. of Oncology, Vejle, Denmark
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT00788957
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT00756444
Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2021-09-21
- Target Recruit Count
- 65
- Registration Number
- NCT00655499
- Locations
- 🇫🇷
Hopital Clinique Claude Bernard, Metz, France
🇫🇷Hopital Prive Jean Mermoz, Lyon, France
🇫🇷Centre Hospitalier Intercommunal Le Raincy - Montfermeil, Montfermeil, France
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 53
- Registration Number
- NCT00630786
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
- Conditions
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3
- Registration Number
- NCT00613730
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.